Si-Bone Inc. (SIBN)
Summary
Bears are Losing Control Over Si-Bone (SIBN), Here's Why It's a 'Buy' Now
Si-Bone (SIBN) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Wall Street Analysts Predict a 71.13% Upside in Si-Bone (SIBN): Here's What You Should Know
The average of price targets set by Wall Street analysts indicates a potential upside of 71.1% in Si-Bone (SIBN). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
How Much Upside is Left in Si-Bone (SIBN)? Wall Street Analysts Think 65.27%
The consensus price target hints at a 65.3% upside potential for Si-Bone (SIBN). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Si-Bone Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 20 | $280.57 | $346.4 | $65.83 | 23.46% |
| SN Stephanie Nee HARBOR CAPITAL ADVISORS Inc. | 246,795 | $3.49M | $4.28M | $788,868.92 | 22.62% |
| BG Bart Gancher Intech Investment Management LLC | 11,091 | $155,605.74 | $191,874.3 | $36,268.56 | 23.31% |
 Point72 Asset Management LP Point72 Asset Management LP | 840,346 | $14.42M | $14.5M | $79,001.79 | 0.55% |
 Joseph Castro Nuveen LLC | 1.29M | $18.53M | $22.12M | $3.59M | 19.38% |
Si-Bone Inc. (SIBN) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Si-Bone Inc. ever had a stock split?
Si-Bone Inc. Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Laura A. Francis CEO | NASDAQ (NMS) Exchange | 825704109 CUSIP |
| US Country | 376 Employees | - Last Dividend | - Last Split | 17 Oct 2018 IPO Date |
Overview
SI-BONE, Inc. is a pioneering medical device company focused on tackling musculoskeletal disorders specifically related to the sacropelvic anatomy. With operations extending across the United States and internationally, SI-BONE aims to bring innovative solutions to common but complex problems such as sacroiliac joint dysfunction, adult spinal deformities, degeneration, and pelvic trauma through its minimally invasive surgical implant systems. Since its inception in 2008, the company has been at the forefront of medical device technology, building a name for itself in the industry. Headquartered in Santa Clara, California, SI-BONE has dedicated itself to improving patient outcomes while reducing recovery times, leveraging a combination of advanced technology and clinical understanding to meet the needs of patients and healthcare providers alike.
Products and Services
- iFuse-3D
A revolutionary titanium implant that epitomizes the fusion of form and function. The iFuse-3D has been uniquely designed, incorporating a triangular cross-section with a 3D-printed porous surface to enhance osseointegration, along with a fenestrated design to allow for bone in-growth. This product is specifically engineered to address sacroiliac joint dysfunction, offering patients a potentially faster recovery and improved surgical outcomes.
- iFuse-TORQ
Specifically designed for the treatment of pelvic trauma, the iFuse-TORQ represents a leap in implant technology. These 3D-printed threaded implants are meticulously crafted to promote healing in the pelvic region following traumatic injury. The innovative design aims to provide stable fixation during the critical healing period, demonstrating SI-BONE’s commitment to addressing complex pelvic injuries through state-of-the-art solutions.
- iFuse Bedrock Granite
The iFuse Bedrock Granite implant sets a new standard for sacroiliac fusion and sacropelvic fixation. Intended as a foundational element for segmental spinal fusion, this product underscores the importance of a stable sacropelvic region in overall spinal health. Its design focuses on creating a reliable base for further spinal fusion procedures, thereby enhancing the stability and success rates of complex spinal surgeries.
